Chaperon Participates in Global Bio Conference... "Discussing Technology Transfer for Atopic Dermatitis Treatments"

Immuno-innovative drug development company Shaperon announced on the 22nd that it participated in ‘Bio Japan 2024,’ held in Yokohama, Japan from the 9th to the 11th, where it engaged in discussions on technology transfer and collaboration with global pharmaceutical companies. This event is expected to accelerate Shaperon’s entry into the global market for its major pipelines.

Bio Japan is Asia’s largest pharmaceutical and biotech event, with about 1,500 multinational pharmaceutical and biotech companies participating to discuss technology transfer and new drug co-development. Since its first event in 1968, it has been the biotechnology conference with the longest history in the world.

At this conference, Shaperon discussed partnerships with approximately 14 pharmaceutical companies for the technology transfer of its major pipelines, including NuGel, an atopic dermatitis treatment currently in Phase 2 clinical trials in the United States. Several of the world’s largest pharmaceutical companies showed great interest not only in synthetic new drug candidates but also in the antibody platform technology called ‘NanoMab.’

Among Shaperon’s pipelines, NuGel, which received significant attention, is the world’s first atopic dermatitis treatment with a mechanism that inhibits the inflammasome complex. It acts on the GPCR19 receptor to block both the initiation and amplification stages of inflammasome activation without causing severe immunosuppressive side effects, while also increasing the number of regulatory T lymphocytes to suppress the activation of adaptive immune system T lymphocytes.

NuGel is currently undergoing a Phase 2b clinical trial in the United States targeting patients with mild to moderate atopic dermatitis. This year, Part 1 of the trial was completed to confirm side effects and optimal dosage in a multiethnic population including Caucasians, and starting next year, Part 2 will verify safety and efficacy in various ethnic groups based on two confirmed optimal dosages.

In addition to Bio Japan, Shaperon also participated in the ‘China Bio Partnering Forum 2024’ held in Shanghai, China in September, where it held collaboration discussions with 19 global pharmaceutical companies. NuGel attracted considerable interest from many global pharmaceutical companies at that conference as well, and more detailed discussions are underway with several large Chinese pharmaceutical companies.

A Shaperon representative stated, “Given that our major pipelines have received great attention from global pharmaceutical companies at recent Asian events including Bio Japan, we expect opportunities for technology transfer to increase further. We will continue to pursue technology transfers through global partnering meetings and strive to achieve good results with companies currently in discussion.”

This content was produced with the assistance of AI translation services.